Zydus Lifesciences Ltd scheduled to meet in May 2026 to approve Q4 FY26

board is scheduled to meet in May 2026 to approve Q4 FY26 and FY26 results, with analysts projecting 10-14% YoY revenue growth to ₹5,400-5,800 Cr and PAT of ₹950-1,050 Cr. The trading window closed from April 1, 2026, until results declaration, amid USFDA approvals for Dapagliflozin Tablets and Pembrolizumab biosimilar FYB206 development milestone. Shares traded at ₹871-₹915.40, down 2.84%, with mcap ₹92,111 Cr and promoter holding at 75%.